Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs YieldMax MSTR Option Income Strategy ETF (MSTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs YieldMax MSTR Option Income Strategy ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while YieldMax MSTR Option Income Strategy ETF trades at $14.19 (market cap $1.14B). The key difference: YieldMax MSTR Option Income Strategy ETF is the larger of the two by market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, YieldMax MSTR Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and YieldMax MSTR Option Income Strategy ETF for 31 Days on average.
| MRVI | MSTY | |
|---|---|---|
Market Cap | $972.90M | $1.14B |
Volume | 4,325,710 | 1,611,783 |
Sector | Health | Income / Options Overlay |
52-Week High | $9.00 | $63.60 |
52-Week Low | $2.83 | $11.55 |
Typical Hold Time | 0 Days | 31 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
MSTY trades at $15.52, down 0.13% on the day, with a bearish technical outlook as moving averages signal selling pressure. The ETF's high distribution rate, exceeding 100% annualized, is a key feature but has coincided with significant NAV erosion, as noted in recent financial media. Recent weekly dividend announcements from YieldMax highlight the income focus, but underlying asset volatility remains a concern.
The outlook is cautious; while the high yield is attractive for income-seeking investors, it comes with substantial risk of principal depletion. Analyst sentiment is mixed, balancing the tactical income opportunity against structural concerns about the fund's long-term sustainability in volatile markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About YieldMax MSTR Option Income Strategy ETF
MSTY is an actively managed ETF that pursues a synthetic covered call strategy on MicroStrategy Incorporated (MSTR) stock. The fund primarily sells call options on MSTR and invests in U.S. Treasury securities and other high-quality collateral. Its goal is to generate monthly income from the option premiums. This strategy provides exposure to the volatile, Bitcoin-correlated growth potential of MSTR while seeking to deliver a high yield, though it caps the potential capital appreciation of the stock.
Read more on MSTY →
